Literature DB >> 11573031

Changes in premenstrual symptoms in women with schizophrenia: a prospective study.

S H Choi1, S B Kang, S H Joe.   

Abstract

OBJECTIVE: We investigated whether the psychiatric symptoms and clinical features of schizophrenia change during the premenstrual phase in female patients.
METHODS: We observed 30 female schizophrenic inpatients over one menstrual cycle. All subjects met DSM-IV criteria for schizophrenia, and all had a regular menstrual cycle. All subjects completed the Daily Rating Form (DRF) every evening, and one psychiatrist rated the subjects (using the Brief Psychiatric Rating Scale [BPRS]) once during each of the three menstrual phases (premenstrual, menstrual, and postmenstrual). Serum levels of estradiol (E2) and progesterone were measured on the fifth to seventh day of both the premenstrual and postmenstrual phases. Data from the 24 subjects who completed the DRF correctly and completely were used for statistical analysis.
RESULTS: The mean total BPRS score for the 24 subjects was highest in the premenstrual phase and lowest in the postmenstrual phase, and a statistically significant difference was found among the three menstrual phases. Mean subtotal BPRS scores showed statistically significant differences among the three menstrual phases in anxiety/depression and withdrawal/retardation, but not in the psychotic symptom subscales. Mean serum E2 level showed a trend of increasing from the premenstrual phase to the postmenstrual phase. However, there was no significant correlation between DeltaBPRS and DeltaE2. When the criterion of 30% change was applied, the DRF items of depressed mood, anxious/nervous/restless, hostile/aggressive, and less/impaired work showed high frequencies of change in the premenstrual phase. Somatic items of abdominal pain, breast pain, and headache showed significant change with the 30% change rule on the DRF. On both the BPRS and DRF scores, premenstrual change of affective and behavioral symptoms was prominent, whereas the change of psychotic symptoms was minimal on the BPRS. In addition, in the premenstrual phase, there was a statistically significant correlation between the total BPRS score and the mean total DRF score. There was no correlation between premenstrual change in symptoms and hormonal levels of E2, progesterone, and the estradiol/progesterone (E/P) ratio.
CONCLUSIONS: The findings of this study suggest that premenstrual exacerbation of schizophrenic symptoms in female patients may not be a worsening of the schizophrenic symptoms but a concurrence of affective, behavioral, and somatic symptoms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11573031     DOI: 10.1097/00006842-200109000-00016

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  11 in total

1.  Premenstrual dysphoric disorder: burden of illness and treatment update.

Authors:  Teri Pearlstein; Meir Steiner
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

Review 2.  Role of estrogen treatment in the management of schizophrenia.

Authors:  Jayashri Kulkarni; Emmy Gavrilidis; Roisin Worsley; Emily Hayes
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

3.  Menstrual Cycle in Schizophrenic Patients: Review with a Case.

Authors:  İpek Sönmez; Ferdi Köşger
Journal:  Noro Psikiyatr Ars       Date:  2015-12-01       Impact factor: 1.339

Review 4.  Menstrual cycle-related exacerbation of disease.

Authors:  Joann V Pinkerton; Christine J Guico-Pabia; Hugh S Taylor
Journal:  Am J Obstet Gynecol       Date:  2010-03       Impact factor: 8.661

5.  Peripheral oxytocin is associated with reduced symptom severity in schizophrenia.

Authors:  Leah H Rubin; C Sue Carter; Lauren Drogos; Hossein Pournajafi-Nazarloo; John A Sweeney; Pauline M Maki
Journal:  Schizophr Res       Date:  2010-10-13       Impact factor: 4.939

Review 6.  Premenstrual exacerbation of mental health disorders: a systematic review of prospective studies.

Authors:  Louise Nora Nolan; Liz Hughes
Journal:  Arch Womens Ment Health       Date:  2022-07-22       Impact factor: 4.405

Review 7.  Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Treatment of depression associated with the menstrual cycle: premenstrual dysphoria, postpartum depression, and the perimenopause.

Authors:  Ellen W Freeman
Journal:  Dialogues Clin Neurosci       Date:  2002-06       Impact factor: 5.986

9.  Exacerbation of Psychosis During the Perimenstrual Phase of the Menstrual Cycle: Systematic Review and Meta-analysis.

Authors:  Thomas J Reilly; Vanessa C Sagnay de la Bastida; Dan W Joyce; Alexis E Cullen; Philip McGuire
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

10.  The role of oestrogen and other hormones in the pathophysiology and treatment of schizophrenia.

Authors:  Emily Hayes; Emorfia Gavrilidis; Jayashri Kulkarni
Journal:  Schizophr Res Treatment       Date:  2012-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.